二肽基肽酶-4抑制剂可有效和安全作用的糖尿病类型

H. Yanai, H. Adachi
{"title":"二肽基肽酶-4抑制剂可有效和安全作用的糖尿病类型","authors":"H. Yanai, H. Adachi","doi":"10.2174/1876524601104010001","DOIUrl":null,"url":null,"abstract":"Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent the inactivation of glucagon-like peptide-1 (GLP-1). This protein, released from the gut following ingestion of a meal, stimulates insulin secretion and inhibits glucagon secretion. Compared with other anti-diabetic drugs, the pharmacological characteristics of DDP-4 inhibitor include improvement in postprandial hyperglycemia, low frequency of hypoglycemia, prevention of development of obesity, few adverse events. Taking account of pharmacological characteristic and our therapeutic experiences with DPP-4 inhibitor, we believe that DPP-4 inhibitor may be a useful and safe oral anti-diabetic drug for diabetes in the elderly people, diabetes complicated with obesity, chronic hepatitis/liver cirrhosis, and steroid-induced diabetes.","PeriodicalId":22762,"journal":{"name":"The Open Diabetes Journal","volume":"26 1","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Types of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely\",\"authors\":\"H. Yanai, H. Adachi\",\"doi\":\"10.2174/1876524601104010001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent the inactivation of glucagon-like peptide-1 (GLP-1). This protein, released from the gut following ingestion of a meal, stimulates insulin secretion and inhibits glucagon secretion. Compared with other anti-diabetic drugs, the pharmacological characteristics of DDP-4 inhibitor include improvement in postprandial hyperglycemia, low frequency of hypoglycemia, prevention of development of obesity, few adverse events. Taking account of pharmacological characteristic and our therapeutic experiences with DPP-4 inhibitor, we believe that DPP-4 inhibitor may be a useful and safe oral anti-diabetic drug for diabetes in the elderly people, diabetes complicated with obesity, chronic hepatitis/liver cirrhosis, and steroid-induced diabetes.\",\"PeriodicalId\":22762,\"journal\":{\"name\":\"The Open Diabetes Journal\",\"volume\":\"26 1\",\"pages\":\"1-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Open Diabetes Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1876524601104010001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open Diabetes Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876524601104010001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

二肽基肽酶-4 (DPP-4)抑制剂可防止胰高血糖素样肽-1 (GLP-1)失活。这种蛋白质在进食后从肠道释放出来,刺激胰岛素分泌,抑制胰高血糖素分泌。与其他降糖药相比,DDP-4抑制剂具有改善餐后高血糖、低血糖发生率低、预防肥胖发生、不良事件少等药理特点。考虑到DPP-4抑制剂的药理特点和我们的治疗经验,我们认为DPP-4抑制剂可能是一种有效和安全的口服降糖药,适用于老年糖尿病、糖尿病合并肥胖、慢性肝炎/肝硬化和类固醇性糖尿病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Types of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely
Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent the inactivation of glucagon-like peptide-1 (GLP-1). This protein, released from the gut following ingestion of a meal, stimulates insulin secretion and inhibits glucagon secretion. Compared with other anti-diabetic drugs, the pharmacological characteristics of DDP-4 inhibitor include improvement in postprandial hyperglycemia, low frequency of hypoglycemia, prevention of development of obesity, few adverse events. Taking account of pharmacological characteristic and our therapeutic experiences with DPP-4 inhibitor, we believe that DPP-4 inhibitor may be a useful and safe oral anti-diabetic drug for diabetes in the elderly people, diabetes complicated with obesity, chronic hepatitis/liver cirrhosis, and steroid-induced diabetes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Gene Expression of GSK3 in Type II Diabetics Compared to Non-Diabetics (ex vivo) G6PC2 rs560887 Gene Variant is Associated with Fasting Blood Glucose in the Admixed Mexican Population Role of Vitamin D Receptor in Prediabetes To Tell or Not to Tell: Disclosure and Self-Management among Adults with Early-Onset Type 2 Diabetes: A Qualitative Study Assessment of Cardiovascular Disease Risk among Qatari Patients with Type 2 Diabetes Mellitus, Attending Primary Health Care Centers, 2014
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1